Strain differences in the expression of endocannabinoid genes and in cannabinoid receptor binding in the brain of Lewis and Fischer 344 rats

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 53, Issue , 2014, Pages 15-22

  Coria, Santiago M ^a   Roura Martínez, David ^a   Ucha, Marcos ^a   Assis, María Amparo ^a   Miguéns, Miguel ^a   García Lecumberri, Carmen ^a   Higuera Matas, Alejandro ^a   Ambrosio, Emilio ^a  

^a UNIVERSIDAD NACIONAL DE EDUCACIÓN A DISTANCIA   (Spain)

Author keywords

CNR1; Endocannabinoid system; FAAH; Lewis and Fischer 344 rats; NAPE PLD

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR; ENDOCANNABINOID; FATTY ACID AMIDASE; PHOSPHOLIPASE D; TRITIUM; 3-(2-HYDROXY-4-(1,1-DIMETHYLHEPTYL)PHENYL)-4-(3-HYDROXYPROPYL)CYCLOHEXANOL; AMIDASE; CYCLOHEXANOL DERIVATIVE; FATTY-ACID AMIDE HYDROLASE; G PROTEIN COUPLED RECEPTOR; GPR55 PROTEIN, RAT; IMMUNOSUPPRESSIVE AGENT; LIPOPROTEIN LIPASE; NAPE-PLD PROTEIN, RAT; PROTEIN BINDING;

ARTICLE; AUTORADIOGRAPHY; CNR1 GENE; CONTROLLED STUDY; DRUG ABUSE; FISCHER 344 RAT; GENE EXPRESSION; GLOBUS PALLIDUS; LEWIS RAT; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; RAT; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR BINDING; STRAIN DIFFERENCE; ANIMAL; BRAIN; DRUG EFFECTS; GENETICS; METABOLISM; RADIOGRAPHY; SPECIES DIFFERENCE;

AMIDOHYDROLASES; ANIMALS; AUTORADIOGRAPHY; BRAIN; CYCLOHEXANOLS; IMMUNOSUPPRESSIVE AGENTS; LIPOPROTEIN LIPASE; MALE; PHOSPHOLIPASE D; PROTEIN BINDING; RATS; RATS, INBRED F344; RATS, INBRED LEW; RECEPTOR, CANNABINOID, CB1; RECEPTORS, CANNABINOID; RECEPTORS, G-PROTEIN-COUPLED; SPECIES SPECIFICITY; TRITIUM;

EID: 84896943343     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2014.02.012     Document Type: Article

References (54)

1. Alexander G.E., Crutcher M.D. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci 1990, 13:266-271.
2. Altarifi A.A., Miller L.L., Negus S.S. Role of micro-opioid receptor reserve and micro-agonist efficacy as determinants of the effects of micro-agonists on intracranial self-stimulation in rats. Behav Pharmacol 2012, 23:678-692.
3. Berrendero F., Robledo P., Trigo J.M., Martin-Garcia E., Maldonado R. Neurobiological mechanisms involved in nicotine dependence and reward: participation of the endogenous opioid system. Neurosci Biobehav Rev 2010, 35:220-231.
4. Busquets-Garcia A., Puighermanal E., Pastor A., de la Torre R., Maldonado R., Ozaita A. Differential role of anandamide and 2-arachidonoylglycerol in memory and anxiety-like responses. Biol Psychiatry 2011, 70:479-486.
5. Camp D.M., Browman K.E., Robinson T.E. The effects of methamphetamine and cocaine on motor behavior and extracellular dopamine in the ventral striatum of Lewis versus Fischer 344 rats. Brain Res 1994, 668:180-193.
6. Chaouloff F., Kulikov A., Sarrieau A., Castanon N., Mormede P. Male Fischer 344 and Lewis rats display differences in locomotor reactivity, but not in anxiety-related behaviours: relationship with the hippocampal serotonergic system. Brain Res 1995, 693:169-178.
7. Cohen J. A power primer. Psychol Bull 1992, 112:155-159.
8. Corchero J., Manzanares J., Fuentes J.A. Cannabinoid/opioid crosstalk in the central nervous system. Crit Rev Neurobiol 2004, 16:159-172.
9. Drakenberg K., Nikoshkov A., Horvath M.C., Fagergren P., Gharibyan A., Saarelainen K., et al. Mu opioid receptor A118G polymorphism in association with striatal opioid neuropeptide gene expression in heroin abusers. Proc Natl Acad Sci U S A 2006, 103:7883-7888.
10. Duvauchelle C.L., Fleming S.M., Kornetsky C. Involvement of delta- and mu-opioid receptors in the potentiation of brain-stimulation reward. Eur J Pharmacol 1996, 316:137-143.
11. Fattore L., Cossu G., Spano M.S., Deiana S., Fadda P., Scherma M., et al. Cannabinoids and reward: interactions with the opioid system. Crit Rev Neurobiol 2004, 16:147-158.
12. Fattore L., Deiana S., Spano S.M., Cossu G., Fadda P., Scherma M., et al. Endocannabinoid system and opioid addiction: behavioural aspects. Pharmacol Biochem Behav 2005, 81:343-359.
13. Fattore L., Vigano D., Fadda P., Rubino T., Fratta W., Parolaro D. Bidirectional regulation of mu-opioid and CB1-cannabinoid receptor in rats self-administering heroin or WIN 55,212-2. Eur J Neurosci 2007, 25:2191-2200.
14. Fole A., Gonzalez-Martin C., Huarte C., Alguacil L.F., Ambrosio E., Del Olmo N. Effects of chronic cocaine administration on spatial learning and hippocampal spine density in two genetically different strains of rats. Neurobiol Learn Mem 2011, 95:491-497.
15. Garcia-Gutierrez M.S., Ortega-Alvaro A., Busquets-Garcia A., Perez-Ortiz J.M., Caltana L., Ricatti M.J., et al. Synaptic plasticity alterations associated with memory impairment induced by deletion of CB2 cannabinoid receptors. Neuropharmacology 2013, 73:388-396.
16. Han J., Kesner P., Metna-Laurent M., Duan T., Xu L., Georges F., et al. Acute cannabinoids impair working memory through astroglial CB1 receptor modulation of hippocampal LTD. Cell 2012, 148:1039-1050.
17. Herkenham M. Characterization and localization of cannabinoid receptors in brain: an in vitro technique using slide-mounted tissue sections. NIDA Res Monogr 1991, 112:129-145.
18. Herradon G., Morales L., Alguacil L.F. Differences of mu-opioid receptors between Lewis and F344 rats. Life Sci 2003, 73:1537-1542.
19. Higuera-Matas A., Montoya G.L., Coria S.M., Miguens M., Garcia-Lecumberri C., Ambrosio E. Differential gene expression in the nucleus accumbens and frontal cortex of Lewis and Fischer 344 rats relevant to drug addiction. Curr Neuropharmacol 2011, 9:143-150.
20. Hojo M., Sudo Y., Ando Y., Minami K., Takada M., Matsubara T., et al. mu-Opioid receptor forms a functional heterodimer with cannabinoid CB1 receptor: electrophysiological and FRET assay analysis. J Pharmacol Sci 2008, 108:308-319.
21. Karimi S., Azizi P., Shamsizadeh A., Haghparast A. Role of intra-accumbal cannabinoid CB1 receptors in the potentiation, acquisition and expression of morphine-induced conditioned place preference. Behav Brain Res 2013, 247:125-131.
22. Kosten T.A., Ambrosio E. HPA axis function and drug addictive behaviors: insights from studies with Lewis and Fischer 344 inbred rats. Psychoneuroendocrinology 2002, 27:35-69.
23. Le Merrer J., Becker J.A., Befort K., Kieffer B.L. Reward processing by the opioid system in the brain. Physiol Rev 2009, 89:1379-1412.
24. Lepore M., Liu X., Savage V., Matalon D., Gardner E.L. Genetic differences in delta 9-tetrahydrocannabinol-induced facilitation of brain stimulation reward as measured by a rate-frequency curve-shift electrical brain stimulation paradigm in three different rat strains. Life Sci 1996, 58:PL365-PL372.
25. Lindley S.E., Bengoechea T.G., Wong D.L., Schatzberg A.F. Strain differences in mesotelencephalic dopaminergic neuronal regulation between Fischer 344 and Lewis rats. Brain Res 1999, 832:152-158.
26. Lopez-Moreno J.A., Lopez-Jimenez A., Gorriti M.A., de Fonseca F.R. Functional interactions between endogenous cannabinoid and opioid systems: focus on alcohol, genetics and drug-addicted behaviors. Curr Drug Targets 2010, 11:406-428.
27. Mackie K. Cannabinoid receptor homo- and heterodimerization. Life Sci 2005, 77:1667-1673.
28. Maguire D.R., Yang W., France C.P. Interactions between mu-opioid receptor agonists and cannabinoid receptor agonists in rhesus monkeys: antinociception, drug discrimination, and drug self-administration. J Pharmacol Exp Ther 2013, 345:354-362.
29. Manzanares J., Corchero J., Romero J., Fernandez-Ruiz J.J., Ramos J.A., Fuentes J.A. Chronic administration of cannabinoids regulates proenkephalin mRNA levels in selected regions of the rat brain. Brain Res Mol Brain Res 1998, 55:126-132.
30. Martin S., Lyupina Y., Crespo J.A., Gonzalez B., Garcia-Lecumberri C., Ambrosio E. Genetic differences in NMDA and D1 receptor levels, and operant responding for food and morphine in Lewis and Fischer 344 rats. Brain Res 2003, 973:205-213.
31. Parent A., Hazrati L.N. Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidum in basal ganglia circuitry. Brain Res Brain Res Rev 1995, 20:128-154.
32. Parolaro D., Rubino T., Vigano D., Massi P., Guidali C., Realini N. Cellular mechanisms underlying the interaction between cannabinoid and opioid system. Curr Drug Targets 2010, 11:393-405.
33. Patel S., Rademacher D.J., Hillard C.J. Differential regulation of the endocannabinoids anandamide and 2-arachidonylglycerol within the limbic forebrain by dopamine receptor activity. J Pharmacol Exp Ther 2003, 306:880-888.
34. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 2005, Elsevier Academic Press, Burlington, Ma. 5th ed.
35. Pickel V.M., Chan J., Kash T.L., Rodriguez J.J., MacKie K. Compartment-specific localization of cannabinoid 1 (CB1) and mu-opioid receptors in rat nucleus accumbens. Neuroscience 2004, 127:101-112.
36. Puighermanal E., Marsicano G., Busquets-Garcia A., Lutz B., Maldonado R., Ozaita A. Cannabinoid modulation of hippocampal long-term memory is mediated by mTOR signaling. Nat Neurosci 2009, 12:1152-1158.
37. Rios C., Gomes I., Devi L.A. mu opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis. Br J Pharmacol 2006, 148:387-395.
38. Rivera P., Miguens M., Coria S.M., Rubio L., Higuera-Matas A., Bermudez-Silva F.J., et al. Cocaine self-administration differentially modulates the expression of endogenous cannabinoid system-related proteins in the hippocampus of Lewis vs. Fischer 344 rats. Int J Neuropsychopharmacol 2013, 16:1277-1293.
39. Robinson L., McKillop-Smith S., Ross N.L., Pertwee R.G., Hampson R.E., Platt B., et al. Hippocampal endocannabinoids inhibit spatial learning and limit spatial memory in rats. Psychopharmacology (Berl) 2008, 198:551-563.
40. Robledo P., Berrendero F., Ozaita A., Maldonado R. Advances in the field of cannabinoid-opioid cross-talk. Addict Biol 2008, 13:213-224.
41. Rodriguez J.J., Mackie K., Pickel V.M. Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat caudate putamen nucleus. J Neurosci 2001, 21:823-833.
42. Salio C., Fischer J., Franzoni M.F., Mackie K., Kaneko T., Conrath M. CB1-cannabinoid and mu-opioid receptor co-localization on postsynaptic target in the rat dorsal horn. Neuroreport 2001, 12:3689-3692.
43. Sanchez-Cardoso P., Higuera-Matas A., Martin S., del Olmo N., Miguens M., Garcia-Lecumberri C., et al. Modulation of the endogenous opioid system after morphine self-administration and during its extinction: a study in Lewis and Fischer 344 rats. Neuropharmacology 2007, 52:931-948.
44. Sanchez-Cardoso P., Higuera-Matas A., Martin S., Miguens M., Del Olmo N., Garcia-Lecumberri C., et al. Strain differences between Lewis and Fischer 344 rats in the modulation of dopaminergic receptors after morphine self-administration and during extinction. Neuropharmacology 2009, 57:8-17.
45. Scavone J.L., Sterling R.C., Van Bockstaele E.J. Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal. Neuroscience 2013, 248:637-654.
46. Schoffelmeer A.N., Hogenboom F., Wardeh G., De Vries T.J. Interactions between CB1 cannabinoid and mu opioid receptors mediating inhibition of neurotransmitter release in rat nucleus accumbens core. Neuropharmacology 2006, 51:773-781.
47. Skripuletz T., Kruschinski C., Pabst R., von Horsten S., Stephan M. Postnatal experiences influence the behavior in adult male and female Fischer and Lewis rats. Int J Dev Neurosci 2010, 28:561-571.
48. Uhl G.R., Drgon T., Johnson C., Fatusin O.O., Liu Q.R., Contoreggi C., et al. "Higher order" addiction molecular genetics: convergent data from genome-wide association in humans and mice. Biochem Pharmacol 2008, 75:98-111.
49. van der Staay F.J., Schuurman T., van Reenen C.G., Korte S.M. Emotional reactivity and cognitive performance in aversively motivated tasks: a comparison between four rat strains. Behav Brain Funct 2009, 5:50.
50. Vigano D., Rubino T., Parolaro D. Molecular and cellular basis of cannabinoid and opioid interactions. Pharmacol Biochem Behav 2005, 81:360-368.
51. Vigano D., Rubino T., Vaccani A., Bianchessi S., Marmorato P., Castiglioni C., et al. Molecular mechanisms involved in the asymmetric interaction between cannabinoid and opioid systems. Psychopharmacology (Berl) 2005, 182:527-536.
52. Vit J.P., Clauw D.J., Moallem T., Boudah A., Ohara P.T., Jasmin L. Analgesia and hyperalgesia from CRF receptor modulation in the central nervous system of Fischer and Lewis rats. Pain 2006, 121:241-260.
53. Viveros M.P., Marco E.M., Llorente R., Lopez-Gallardo M. Endocannabinoid system and synaptic plasticity: implications for emotional responses. Neural Plast 2007, 52908.
54. Zhang R.R., Zhang W.C., Wang J.Y., Guo J.Y. The opioid placebo analgesia is mediated exclusively through mu-opioid receptor in rat. Int J Neuropsychopharmacol 2013, 16:849-856.